Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Zai Lab Limited American Depositary Shares

ZLAB

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Last trade $23.41
Day change -$0.06 (-0.26%)
Day range $23.06 – $23.90
Volume 439,816
Market cap $2.93B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.93B
Price / earnings
—
Price / book
5.2×
Price / sales
6.63×
EV / sales
5.96×
EV / EBITDA
-10.06×

Profitability

Earnings per share
-$1.59
Return on assets
-19.38%
Return on equity
-35.22%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.45×
Current ratio
2.04×
Quick ratio
1.84×
Cash ratio
1.3×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$163.34M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ZLAB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$108.21M$106.31M$99.61M$127.6M$116.1M$109.98M$106.49M$109.07M
Cost of revenue$51.31M$48.16M$38.34M$62.33M$46.88M$43M$38.65M$42.09M
Gross profit$56.9M$58.15M$61.28M$65.27M$69.21M$66.97M$67.84M$66.98M
Selling, general and administrative$70.07M$72.87M$65.07M$73.04M$70.11M$71.04M$63.42M$82.62M
Research and development$49.81M$61.77M$65.59M$61.63M$47.93M$50.61M$60.73M$52.25M
Total operating expenses$119.88M$134.64M$130.66M$134.67M$118.03M$121.87M$124.15M$134.87M
Operating income-$62.98M-$76.49M-$69.39M-$69.41M-$48.82M-$54.9M-$56.31M-$67.89M
Interest expense-$1.58M-$1.59M-$1.64M-$1.36M-$1.4M-$1.26M-$1.19M-$904K
Income before taxes-$48.01M-$51.85M-$49.58M-$53.34M-$35.96M-$40.73M-$48.44M-$81.68M
Income taxes-$1.87M-$1.02M$1.44M-$2.93M$0$0$0$0
Net income-$46.14M-$50.83M-$51.02M-$50.41M-$35.96M-$40.73M-$48.44M-$81.68M
Net income attributable to common shareholders-$46.14M-$50.83M-$51.02M-$50.41M-$35.96M-$40.73M-$48.44M-$81.68M
EBITDA-$58.57M-$72.32M-$65.44M-$65.49M-$44.92M-$51.16M-$52.85M-$64.86M
Basic earnings per share-$0.04-$0.05-$0.05-$0.05-$0.03-$0.04-$0.04-$0.08
Diluted earnings per share-$0.04-$0.05-$0.05-$0.05-$0.03-$0.04-$0.04-$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

GlobeNewswire Inc.

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab announced a clinical collaboration to evaluate a dual DLL3-targeting combination therapy for small cell lung cancer (SCLC) and neuroendocrine carcinomas. The Phase Ib/II study will test obrixtamig, a DLL3/CD3 T-cell engager, combined with zocilurtatug pelitecan (zoci), a DLL3-targeting ADC. Both drugs have shown encouraging early efficacy and favorable safety profiles in previous trials.

Benzinga

$207B Market Shift: The Race for Fast Track Approval in Oncology

The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.

Benzinga

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Chinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.